Anti-viral Drugs Market Research Report Information, by application (hepatitis, HIV/AIDS, herpes, influenza and others) and by mechanism of action (nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others) - Forecast to 2032

Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s five forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global Anti-Viral Drugs Market, by Application

5.1 Introduction

5.1.1 Hepatitis

5.1.2 HIV/AIDS

5.1.3 Herpes

5.1.4 Influenza

5.1.5 Others

6 Global Anti-Viral Drugs Market, by Mechanism of Action

6.1 Introduction

6.1.1 Nucleotide Polymerase Inhibitors

6.1.2 Reverse Transcriptase Inhibitors

6.1.3 Protease Inhibitors

6.1.4 Others

7 Global Anti-Viral Drugs Market, by Regions

7.1 Introduction

7.1.1 Americas

7.1.1.1 North America

7.1.1.2 South America

7.1.2 Europe

7.1.2.1 Germany

7.1.2.2 France

7.1.2.3 UK

7.1.2.4 Italy

7.1.2.5 Spain

7.1.2.6 Rest of Europe

7.1.3 Asia Pacific

7.1.3.1 Japan

7.1.3.2 China

7.1.3.3 India

7.1.3.4 Republic of Korea

7.1.3.5 Rest of Asia Pacific

7.1.4 Middle East & Africa

8 Company Landscape

8.1 Introduction

8.1.1 Mergers Acquisitions

8.1.2 Collaborations

8.1.3 Release/New Product Launches

8.1.4 Other (Expansion, Updates, Partnership)

9 Company Profile

9.1 Johnson & Johnson

9.1.1 Company Overview

9.1.2 Product/Business Segment Overview

9.1.3 Financials

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.2 Merck & Co. Inc.

9.2.1 Overview

9.2.2 Product/Business Segment Overview

9.2.3 Financials

10.2.4 Key Developments

9.2.5 SWOT Analysis

9.3 Gilead Sciences Inc.

9.3.1 Overview

9.3.2 Product/Business Segment Overview

9.3.3 Financials

9.3.4 Key Developments

9.3.5 SWOT Analysis

9.4 Hoffmann-La Roche Ltd.

9.4.1 Overview

9.4.2 Product/Business Segment Overview

9.4.3 Financials

9.4.4 Key Developments

9.4.5 SWOT Analysis

9.5 GlaxoSmithKline Plc

9.5.1 Overview

9.5.2 Product/Business Segment Overview

9.5.3 Financials

9.5.4 Key Developments

9.5.5 SWOT Analysis

9.6 Abbott Laboratories

9.6.1 Overview

9.6.2 Product/Business Segment Overview

9.6.3 Financials

9.6.4 Key Developments

9.6.5 SWOT Analysis

9.7 Novartis International AG

9.7.1 Overview

9.7.2 Product/Business Segment Overview

9.7.3 Financials

9.7.4 Key Developments

9.7.5 SWOT Analysis

9.8 AstraZeneca AB

9.8.1 Overview

9.8.2 Product/Business Segment Overview

9.8.3 Financials

9.8.4 Key Developments

9.8.5 SWOT Analysis

9.9 Cipla Inc.

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.11 Others

10 Appendix

List of Tables

TABLE 1 GLOBAL ANTI-VIRAL DRUGS MARKET, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL ANTI-VIRAL DRUGS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL ANTI-VIRAL DRUGS MARKET, BY MECHANISM OF ACTION, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL ANTI-VIRAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ANTI-VIRAL DRUGS MARKET, BY APPLICATION

FIGURE 4 GLOBAL ANTI-VIRAL DRUGS MARKET, BY MECHANISM OF ACTION

FIGURE 5 GLOBAL ANTI-VIRAL DRUGS MARKET, BY REGION

FIGURE 6 GLOBAL ANTI-VIRAL DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)